Skip to main content
. Author manuscript; available in PMC: 2020 Oct 17.
Published in final edited form as: Lancet Neurol. 2011 Aug 3;10(9):806–818. doi: 10.1016/S1474-4422(11)70155-7

Table 3:

Results from repeat measurement of FGF-21 in serum, listed by patients’ numbers

Diagnosis FGF-21 concentration in serum (pg/mL)
Disease progression between measurements
2009 or 2010 2011

4 MELAS   580 1048 Active disease progression
15 Mitochondrial myopathy   586   915 Moderate disease progression
16 Mitochondrial myopathy   570   514 Stable disease
78 Alpers’ hepatoencephalopathy 1062* 2250 Progressive disease, remitting status epilepticus
*

Analysis done in 2010.